08:03 PM
Top stories

Centre proposes separate licensing framework for wholesale trade of bulk drugs

Centre proposes separate licensing framework for wholesale trade of bulk drugs
Image: Hindustan Times

🤖 Summarise this story with AI:

ChatGPTClaudeGoogle AIPerplexity

This headline comes from Hindustan Times’s public news feed. The full article, images and copyright belong to the publisher.

Explained

What happened

On 19 November, several Indian outlets reported that the Health Ministry has proposed a separate licensing system for wholesale dealing in bulk drugs, the raw active ingredients used to make finished medicines. Hindustan Times and DD India both described the proposal in broad terms, according to their reports.

The Hindu offered more detail. It reported that the ministry has released draft amendments to two existing rulebooks: the New Drugs and Clinical Trials Rules, 2019, and the Drugs Rules, 1945. According to The Hindu, the changes would add antimicrobials to the definition of "New Drug." Manufacturers of antimicrobials would first need permission from the Central Licensing Authority before applying for a licence from a State authority. The report also said the draft would introduce separate forms for the wholesale bulk drug licence. Its account of the forms is cut short in the version available to us, so the specifics are unclear.

Why it matters

The Hindu linked the draft to concerns over antimicrobial resistance, the growing ability of bacteria and other microbes to withstand drugs meant to kill them. In its report, the proposal is presented as a response to those concerns. Under the draft, central approval would sit ahead of the state-level licensing step for antimicrobial makers, which would change the order in which manufacturers deal with the two layers of regulation.

The other reports frame the story mainly as a change to how bulk drug wholesale is licensed, without the antimicrobial angle. Read together, the coverage suggests the proposal affects both the licensing of bulk drug trade and the rules for antimicrobial manufacturers.

What we don't know yet

The available reports are short, and none gives a full text of the draft. Hindustan Times and DD India do not explain the content of the proposed framework beyond its title. The Hindu's account is incomplete, so the details of the new forms and the conditions for central permission remain unclear. The reports also do not say when the draft takes effect, how long the public has to respond, or whether any stakeholder has commented. Readers should check the Health Ministry's official draft notification for the exact wording before drawing conclusions.

Written by the 91News.in desk with AI assistance, based on reports from Hindustan Times, DD India, The Hindu. Updated 19 Nov 2026, 7:05 pm. Spotted an error? Tell us.

Same story from other sources2 reports

More Top stories